|
PLAA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.90870000005283E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.36139999999496E-05 |
| Normal-vs-Stage2 |
8.097400E-03 |
| Normal-vs-Stage3 |
5.56269999951731E-07 |
| Normal-vs-Stage4 |
2.312399999993E-05 |
| Stage1-vs-Stage2 |
6.011600E-01 |
| Stage1-vs-Stage3 |
1.409600E-01 |
| Stage1-vs-Stage4 |
3.709600E-01 |
| Stage2-vs-Stage3 |
1.544990E-01 |
| Stage2-vs-Stage4 |
2.829400E-01 |
| Stage3-vs-Stage4 |
8.292000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.01630000004516E-06 |
| Normal-vs-AfricanAmerican |
5.769500E-02 |
| Normal-vs-Asian |
7.73510000000588E-05 |
| Caucasian-vs-AfricanAmerican |
1.866640E-01 |
| Caucasian-vs-Asian |
8.219200E-01 |
| AfricanAmerican-vs-Asian |
1.705170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65927999999926E-05 |
| Normal-vs-Female |
4.64129999999674E-06 |
| Male-vs-Female |
4.853000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.756120E-04 |
| Normal-vs-Age(41-60Yrs) |
4.16140000014664E-07 |
| Normal-vs-Age(61-80Yrs) |
6.25869999999473E-05 |
| Normal-vs-Age(81-100Yrs) |
2.704200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.666770E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.174200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.745000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.992600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.949800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.612200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.720440E-01 |
| Classical-VS-Follicular |
3.494200E-01 |
| Classical-VS-Other |
1.372240E-01 |
| Classical-VS-Normal |
5.95369999999429E-05 |
| Tall-VS-Follicular |
4.823000E-01 |
| Tall-VS-Other |
3.914200E-01 |
| Tall-VS-Normal |
7.69710000000368E-05 |
| Follicular-VS-Other |
3.184400E-01 |
| Follicular-VS-Normal |
1.974030E-04 |
| Other-VS-Normal |
2.119400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.73093999999985E-05 |
| Normal-vs-N1 |
1.53447999999834E-05 |
| N0-vs-N1 |
3.260800E-01 |
|
|
